All In Biotech

Drug Trial Radar · NCT04915404

Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)

A Multicenter, Open-Label Study of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy

Last checked: Nov 19, 2026Latest source record: Jun 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

5

Actual

Start

Dec 7, 2022

Primary completion

Dec 30, 2023

Study completion Dec 30, 2023

Sponsor

Lead sponsor
WPD Pharmaceuticals Sp. z o.o.Industry
Sponsor type
Industry
Collaborators
Worldwide Clinical Trials; National Center for Research and Development, Poland
First posted
Jun 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, Phase 1b/2 efficacy and safety study of Berubicin utilizing a Simon's 2-stage design to confirm the efficacy (or futility) of a single arm of Berubicin treatment, administered at the recommended Phase 2 dose (RP2D) identified in Phase 1 studies (7.5 mg/m2 Berubicin HCl), on the endpoint of ORR in up to approximately 61 patients. A central reader will determine the radiologic responses for each patient according to m RANO criteria. The responder criteria for this Simon's design will be based on objective response criteria defined as individual patients achieving CR or PR per m-RANO criteria within 6 months from baseline.

Conditions

  • Recurrent Glioblastoma Multiforme

Interventions

  • Berubicin HydrochlorideDrug

    Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base (equivalent to 7.5 mg/m2 Berubicin HCl) as a 2-hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. objective response rate (ORR)Time frame: 6 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Uniwersyteckie Centrum Kliniczne Klinika Onkoligii i Radioterapii

    Gdansk, Poland

  • Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie,Państwowy Instytut Badawczy w Warszawie,Klinika Nowotworów Głowy i Szyi

    Warsaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.